Pharmacokinetics (PK) of lonafarnib (L), a farnesyl protein transferase inhibitor.

被引：0
|
作者：
Zhu, Y [1 ]
Statkevich, P [1 ]
Cutler, DL [1 ]
Calzetta, A [1 ]
Curtis, D [1 ]
Batra, VK [1 ]
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P59 / P59
页数：1
相关论文
共 50 条
  • [31] Modified radiosensitivity of pancreatic cancer xenografts by farnesyl protein transferase inhibitor and MEK inhibitor
    Matsui, Y
    Goto, M
    Iwakawa, M
    Asano, T
    Kenmochi, T
    Imai, T
    Ochiai, T
    ONCOLOGY REPORTS, 2003, 10 (05) : 1525 - 1528
  • [32] INHIBITORS OF FARNESYL - PROTEIN TRANSFERASE
    MILANO, PD
    MAYER, MP
    POULTER, CD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 203 : 72 - ORGN
  • [33] A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors
    Chow, Laura Q. M.
    Eckhardt, S. Gail
    O'Bryant, Cindy L.
    Schultz, Mary Kay
    Morrow, Mark
    Grolnic, Stacy
    Basche, Michele
    Gore, Lia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) : 631 - 646
  • [34] A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors
    Laura Q. M. Chow
    S. Gail Eckhardt
    Cindy L. O’Bryant
    Mary Kay Schultz
    Mark Morrow
    Stacy Grolnic
    Michele Basche
    Lia Gore
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 631 - 646
  • [35] Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-1
    Lobell, RB
    Liu, DM
    Buser, CA
    Davide, JP
    DePuy, E
    Hamilton, K
    Koblan, KS
    Lee, Y
    Mosser, S
    Motzel, SL
    Abbruzzese, JL
    Fuchs, CS
    Rowinsky, EK
    Rubin, EH
    Sharma, S
    Deutsch, PJ
    Mazina, KE
    Morrison, BW
    Wildonger, L
    Yao, SL
    Kohl, NE
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (09) : 747 - 758
  • [36] Pharmacokinetics and metabolism of a Ras farnesyl transferase inhibitor in rats and dogs:: In vitro-in vivo correlation
    Singh, R
    Chen, IW
    Jin, LX
    Silva, MV
    Arison, BH
    Lin, JH
    Wong, BK
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (12) : 1578 - 1587
  • [37] Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor.
    Holen, K. D.
    Belani, C. P.
    Wilding, G.
    Ramalingam, S.
    Heideman, J. L.
    Ramanathan, R. K.
    Bowen, C. J.
    Williams, D. D.
    Hodge, J. P.
    Dar, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 79S - 79S
  • [38] A phase I study of Lonafarnib, a farnesyl transferase inhibitor in combination with herceptin plus paclitaxel in Her 2/neu overexpressing breast cancer
    Schellens, Jan H.
    Dieras, Veronique
    Roelvink, Marja
    Awada, Ahmad
    Govaerts, Anne-Sophie
    Bogaerts, Jan
    Marreaud, Sandrine
    Lacombe, Denis
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3470S - 3471S
  • [39] The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cells
    Niessner, H.
    Sinnberg, T.
    Beck, D.
    Flaherty, K.
    Schaller, M.
    Kulms, D.
    Schittek, B.
    Schadendorf, D.
    Garbe, C.
    Meier, F.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (09): : 739 - 739
  • [40] Rhombenone: Farnesyl protein transferase inhibitor from the leaves of Hedera rhombea Bean
    Kwon, BM
    Lee, SH
    Kim, KS
    Lee, LR
    Lee, UC
    Hong, SH
    Bok, SH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (08) : 971 - 974
12345